Adults who continued using denosumab had a lower risk for developing incident diabetes than adults who discontinued denosumab after the first dose (HR = 0.84; 95% CI, 0.78-0.9).

ADVERSE REACTIONSPostmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and ...

Prolia also carries a Boxed Warning for patients with advanced chronic kidney disease. XGEVA ®: The most frequently reported serious adverse reaction was dyspnea.

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients ...

This is the fourth pair of denosumab biosimilars approved by the agency. Denosumab-bddz (Wyost [high dose]/Jubbonti [low dose]), developed by Sandoz, was the first to receive approval in March 2024.